This week Dr. Mark Lebwohl from Icahn School of Medicine at Mount Sinai joins us to discuss the latest treatment options for psoriasis and his research focusing on new topical therapies for the management of the disease.
Links to the six articles discussed can be found here:
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
This week Dr. Mark Lebwohl from Icahn School of Medicine at Mount Sinai joins us to discuss the latest treatment options for psoriasis and his research focusing on new topical therapies for the management of the disease.
Links to the six articles discussed can be found here:
- Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
- Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
- Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study
- Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis
- Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion inmoderate-to-severe plaque psoriasis: phase 3 open-label study
- Itch: an under-recognized problem in psoriasis
View more
